Video

Justin Gover

Publish date: December 18, 2017

Justin Gover, Chief Executive Officer of Greenwich Biosciences, discusses the FDA's planned review of Epidiolex, a formulation of cannabidiol, for the treatment of Dravet syndrome and Lennox-Gastaut syndrome.

 

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel .

Recommended Reading

What Are the Mechanisms of SUDEP?
MDedge Neurology
Sleep apnea treatment may reduce risk of epileptic seizures
MDedge Neurology
Analysis strengthens association between epilepsy onset, menarche
MDedge Neurology
Faciobrachial dystonic seizures require urgent immunotherapy
MDedge Neurology
Hippocampal features may predispose children with febrile status epilepticus to poorer memory
MDedge Neurology
Continuous bedside monitoring improved safety of intracranial stereotactic EEG
MDedge Neurology
Fenfluramine trials in Dravet syndrome yield highly positive results
MDedge Neurology
ACTH and other standard treatments prove best for infantile spasms
MDedge Neurology
Does Treating Sleep Apnea Improve Seizure Outcomes?
MDedge Neurology
Adherence to Psychotherapy May Improve Outcomes in Patients With Psychogenic Nonepileptic Seizures
MDedge Neurology

Related Articles